Table 2.
Ongoing (actively recruiting) trials utilizing ovarian cancer vaccines.
| Trial | Vaccine | Clinical Trial Phase | Reference (ClinicalTrials.gov Identifier) |
|---|---|---|---|
| Ovarian Cancer Treatment With a Liposome Formulated mRNA Vaccine in Combination With (Neo-)Adjuvant Chemotherapy (OLIVIA) | W_ova1 vaccine, which includes 3 OC TAA RNAs | Phase 1 | NCT04163094 |
| Ovarian Dendritic Cell Vaccine Trial | DC vaccine made with autologous tumor lysate or for patients who are HLA-A2 with peptides of MUC1 and WT1 therapy | Phase 2 | NCT00703105 |
| Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines | DC vaccine | Phase 1/2 | NCT02432378 |
| Study of Oncoimmunome for the Treatment of Stage III/IV Ovarian Carcinoma | OncoImmunome includes a mixture of 7–10 peptides identified based upon tumor-specific mutant peptide sequences from each tumor transcriptome | Phase 1 | NCT02933073 |
| Open Label Immunotherapy Trial for Ovarian Cancer (V3-OVA) | Tableted vaccine (V3-OVA) containing ovarian cancer antigens | Phase 2 | NCT03556566 |
| Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer | DPX-Survivac | Phase 2 | NCT03029403 |
| Vaccine Therapy in Treating Patients With Metastatic Solid Tumors | Combination of 2 chimeric (Trastuzumab-like and Pertuzumab-like) HER-2 vaccine | Phase 1 | NCT01376505 |
| T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer | Aldesleukin, a recombinant human IL-2 | Phase 1 | NCT03318900 |
| Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors | ARG1–18,19,20, an ARG1 peptide vaccine | Phase 1 | NCT03689192 |
| Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin (ORION-01) | Oregovomab, a murine monoclonal antibody against CA125 | Phase 1/2 | NCT03100006 |
| P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Modified vaccinia virus ankara vaccine expressing p53 | Phase 2 | NCT03113487 |
| Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors | Autologous or allogeneic tumor cells | Phase 1/2 | NCT00722228 |
| Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers | galinpepimut-S, a WT1-targeting multivalent heteroclitic peptide vaccine | Phase 1/2 | NCT03761914 |
| DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission | DEC-205/NY-ESO-1 Fusion Protein CDX-1401 | Phase 1/2 | NCT02166905 |
| A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors | DSP-7888, a WT1 protein-derived peptide vaccine | Phase 1/2 | NCT03311334 |
Tables OC: ovarian cancer; RNA: ribonucleic acid; DC: dendritic cell; ARG1: arginase-1; WT1: Wilms Tumor-1.